Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.49 |
| ▸ | ALDH1A2 | O94788 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1419901 | 0.83 | MAPT (0.60) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL5313388 | 0.79 | NPC1 (1.00) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL5738629 | 0.79 | NPC1 (0.76) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL1420335 | 0.77 | ALDH1A3 (0.55) | NPC1RAB9AALDH1A1POLBDHODH | |
| SCHEMBL12828640 | 0.76 | DHODH (0.52) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL5074229 | 0.74 | DHODH (0.67) | NPC1RAB9AALDH1A1POLBDHODH | |
| SCHEMBL7172073 | 0.74 | CRHBP (0.46) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL31367499 | 0.73 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL5737718 | 0.73 | CASP3 (0.64) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL31367460 | 0.73 | ALDH1A1 (0.51) | NPC1RAB9AALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2011-03-31 | — | — | US | disclosed |
| EP-2297144-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009146358-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009146358-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | NPC1 4009/4885RAB9A 825/4885ALDH1A1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.